AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00601250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin
Description: Patients receive linagliptin 5 mg tablets once daily
Study NCT00708175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 30 mg, tablets, orally, once daily for 4 weeks, then increased to Pioglitazone 45 mg, tablets, orally, once daily for up to 48 weeks.
Study NCT00708175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pioglitazone placebo-matching tablets, orally, once daily for up to 52 weeks.
Study NCT00985322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE inhibitor Ramipril
Description: The ACE inhibitor (Ramipril) will be started at 1.25 mg/day and will be up-titrated to 2.5 mg/day, to 5 mg/day, and then to 10 mg/day according to BP control and tolerability.
Study NCT00985322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-RAS inhibitor antihypertensive therapy
Description: Blood Pressure lowering regimen not including RAS inhibitors
Study NCT03217149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: heliox combined with MV
Description: heliox combined with MV is given to infant with ARDS
Study NCT03217149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MV
Description: MV is given to infant with ARDS
Study NCT03641105 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic test
Description: detect the contents of glucose metabolism molecules using mass spectrum
Study NCT05906823 — intervention group
Intervention type: OTHER
Intervention: Detection of pleural effusion
Description: Detection of pleural effusion
Study NCT01578967 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Brentuximab vedotin
Description: IV, 1.8mg/kg, every 3 weeks for 6 cycles.
Study NCT01578967 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ABVD
Description: Doxorubicin - 25mg/m2 IV over 3-5 minutes, Day 1 and 15, every 28 days, 2-6 cycles.~Bleomycin - 10u/m2 IV, Day 1 and 15, every 28 days, 2-6 cycles Vinblastine - 6mg/m2 IV over 3-5 minutes, Day 1 and 15, every 28 days, 2-6 cycles.~Dacarbazine - 375mg/m2 IV over 30 minutes, Day 1 and 15, every 28 days, 2-6 cycles.
Study NCT00527254 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine system
Description: Possibility of sending the SMBG values of the patients to a web page via phone mobile sms messages. The HCP had a password access to this web page to check the blood glucose values of the patients and if necessary send to them sms messages with recommendations.
Study NCT03722056 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic resection
Description: all patients with suspected Gastric GIST undergoes laparoscopic resection. Tumour location decides the approach used for resection. Therefore, a variety of options such as local resections, wedge resections, transgastric resections, intragastric resection and partial gastrectomies were performed.
Study NCT02944994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unified protocol
Description: This is a transdiagnostic cognitive behavioral therapy
Study NCT02944994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Care
Description: This arm will reflect typical care received in routine mental health care
Study NCT04237922 — intervention group
Intervention type: DRUG
Intervention: Prasugrel 10mg
Description: Prasugrel 10mg dispensing claim is used as the exposure group
Study NCT04237922 — intervention group
Intervention type: DRUG
Intervention: Clopidogrel 75mg
Description: Clopidogrel 75 mg dispensing claim is used as the reference group
Study NCT00650572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-380, HER2 inhibitor; oral
Description: Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
Study NCT01685424 — intervention group
Intervention type: DRUG
Intervention: Etoricoxib
Description: As per routine clinical practice in the United Kingdom
Study NCT03759977 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity
Description: The sessions of Adapted Physical Activity will be focus around the theme of balance, with a small part of resistance training.
Study NCT00809081 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Enteral Feeding and Total Parental Support
Description: Enteral Feeding : 20ml/hr on POD1~* Velocity is progressively increased by 20ml/d until full nutritional goal (25Kcal/Kg)
Study NCT00809081 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Enteral Feeding and Total Parental Support
Description: Enteral Feeding : 20ml/hr on POD1~* Velocity is progressively increased by 20ml/d until full nutritional goal (25Kcal/Kg)
Study NCT00447382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: NN304 injected s.c. (under the skin). Given as basal insulin.
Study NCT00447382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Injected s.c. (under the skin). Given as bolus insulin.
Study NCT00447382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Injected s.c. (under the skin). Given as bolus insulin.
Study NCT00447382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: NN729 injected s.c. (under the skin). Given as basal insulin
Study NCT01094119 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: heated pad
Description: patients will be warmed with a heated pad during surgery.
Study NCT03865901 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Mellitus GCD59 Test
Description: An ELISA for screening for the risk of gestational diabetes
Study NCT00308269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vintafolide IV Bolus
Description: Vintafolide is a folic acid desacetylvinblastine hydrazide conjugate
Study NCT00308269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vintafolide IV Infusion
Description: Vintafolide is a folic acid desacetylvinblastine hydrazide conjugate
Study NCT04661501 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AlloDerm
Description: Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.
Study NCT04661501 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AlloMax
Description: Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.
Study NCT04661501 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DermACELL
Description: Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.
Study NCT04661501 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flex HD
Description: Acellular Dermal Matrices (ADMs) are breast reconstruction material. They are donated cadaveric dermis that is aseptically processed or sterilized in order to remove cellular and immunogenic components to prevent host reactions.
Study NCT01862302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: 1mg the night before and 1mg the morning of surgery; OR Haloperidol 2mg the morning of surgery
Study NCT01862302 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 dose the night before and 1 dose the morning of surgery; OR 2 doses the morning of surgery
Study NCT06323200 — intervention group
Intervention type: PROCEDURE
Intervention: lymphaticovenous anastomosis
Description: The patients were under intravenous general anesthesia with local anesthetic infiltration for each incision21. LVs were detected by intradermal injection of ICG into the web spaces between the toes and on the medial and lateral malleoli. ICG flow with linear dermal backflow(DB) patterns was detected immediately using a handheld near-infrared camera. The recipient veins were marked using B-mode echo Doppler, close to the marked linear pattern. In case of DB pattern, the incision was made along the great saphenous vein. A 3 cm incision was made and the lymphatics and recipient veins were identified. All patients underwent supermicrosurgical LVA with 11- 0 nylon sutures using a high-power surgical microscope by a single senior surgeon. LVAs are performed using only antegrade flow lymphatics and lymphaticovenous end-to-end anastomosis (LVEEA) and end-to-side anastomosis (LVESA).
Study NCT02018757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE containing As2O3
Description: transarterial chemoembolization containing a mixture of 20mg of arsenic trioxide, 40mg of adriamycin and some dose of 40% ultra-fluid lipiodol
Study NCT02018757 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TACE containing placebo
Description: transarterial chemoembolization containing a mixture of 20mg of placebo, 40mg of adriamycin and some dose of 40% ultra-fluid lipiodol
Study NCT01674751 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-ordering program
Description: During the 4 week intervention phase, participants use the pre-ordering program, receive a novel, smart receipt upon checkout that will detail the caloric and fat content of what they ordered, and receive price discounts for select low calorie and low fat items. The pre-ordering system is designed to provide the opportunity for the individual to see what is available along with nutritional information and to make a selection ahead of time.
Study NCT01674751 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pre-ordering program
Description: During the 4 week intervention phase, participants use the pre-ordering program, receive a novel, smart receipt upon checkout that will detail the caloric and fat content of what they ordered, and receive price discounts for select low calorie and low fat items. The pre-ordering system is designed to provide the opportunity for the individual to see what is available along with nutritional information and to make a selection ahead of time.
Study NCT06177249 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control vaccine
Description: A group of 652 subjects were vaccinated with the control vaccine at 0, 3, 7, 14 and 28 days (5 doses in total). Blood samples were collected from the subjects at 0, 7/14 and 35/42 days for antibody detection.
Study NCT06177249 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Experimental vaccine
Description: A total of 652 subjects received 5 doses of the vaccine at 0, 3, 7, 14 and 28 days. Blood samples were collected on 0, 7/14 and 35/42 days for antibody detection.
Study NCT03597412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvamibe
Description: Rosuvastatin 10mg/Ezetimibe 10mg
Study NCT03597412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monorova
Description: Rosuvastatin 20mg
Study NCT02712229 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CONNECT
Description: Primary palliative care, care management intervention led by existing oncology nurses. Deployed through a series of nurse-led encounters before or after regularly scheduled oncology visits. Based on best practices in palliative oncology care, the first visit focuses on establishing rapport, addressing symptom needs and choosing a surrogate decision maker. Subsequent visits include additional focus on treatment preferences and future goals.~Visits are guided by patient-reported outcomes. During all encounters, the nurse works with patients/caregivers to complete/update individualized Shared Care Plans. After all visits, the nurse discusses patients' symptoms, preferences and goals with their oncologists via a mandatory check-in session and a follow-up call with the patient and/or caregiver.
Study NCT04487834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simethicone Solution
Description: Oral daily treatment for four weeks
Study NCT04487834 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vivatlac Baby
Description: Oral daily treatment for four weeks
Study NCT00911079 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermia
Description: Single course of Catheter-based Ultrasound Hyperthermia (within approximately 2 hours of a Standard-of-care High Dose Rate (HDR) Brachytherapy)
Study NCT00911079 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDR brachytherapy
Description: Completion of standard-of-care high dose rate (HDR) Brachytherapy treatments (radiation fractions) using Session #1 catheter implants
Study NCT00501527 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapy with modified extract of P. pratense pollen
Description: Sublingual (2 drops daily)
Study NCT00501527 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2 drops daily
Study NCT01725048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine
Description: 7.5mg by mouth once a day at night. If subject has not had a 50% or greater reduction in the PHQ-9 depression assessment score, and if the subject is not experiencing unacceptable adverse effects, then the dose may be escalated first to 15mg by mouth every night and then to 30mg by mouth every night.
Study NCT01725048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Description: Citalopram 10mg by mouth once daily. If the subject has not had a 50% or greater reduction in PHQ-9 depression assessment score, and if the subject is not experiencing unacceptable side effects, then the dose may be escalated first to 20mg by mouth every day and then to 40mg by mouth once a day.
Study NCT02884427 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cathode stimulation
Description: Electrical stimulation through the cathode or negative pole, in which a peripheral nerve will be subject to the passage of a direct current seeking increased excitability and conductivity during the passage of current.
Study NCT02884427 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anode stimulation
Description: Electrical stimulation through the anode or positive pole, in which a peripheral rib will be subjected to the passage of a direct current seeking to reduce excitability and conductivity during the passage of current.
Study NCT00041561 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitrogen gas
Description: Nitrogen gas will be given at 5ppm until Day 28 or extubation
Study NCT00041561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled nitric oxide
Description: inhaled nitric oxide will be given at 5 ppm until day 28 or extubation
Study NCT02884427 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Current application without the actual electric conduction to the person occurs. This will be achieved by adjusting parameters while installing another channel and not one that is working.
Study NCT01024413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: study arm.erlotinib 150 mg oral till disease progression
Study NCT00520104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal ketamine
Description: drug interaction
Study NCT03412370 — intervention group
Intervention type: OTHER
Intervention: Cognitive Assessment
Description: Complete cognitive assessments
Study NCT03412370 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT03855553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Based Treatment
Description: 10 families will be randomized to receive 10 - 16 weeks of Family Based Treatment (FBT), the gold standard in eating disorder treatment for adolescents. FBT is a highly structured behavioral intervention in which caregivers are charged with the primary task of re-feeding their child and normalizing his or her eating behaviors and weight status.
Study NCT03855553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Cognitive Behavioral Therapy
Description: 10 families will be randomized to receive 10 - 16 weeks of Enhanced Cognitive Behavioral Therapy (CBT-E), a clinically validated treatment for adolescent eating disorders. CBT-E is a short-term, individual treatment focused on normalizing eating behaviors and modifying underlying cognitions that contribute to the maintenance of eating disorder behaviors (e.g., over-importance of shape and weight in one's self-evaluation).
Study NCT01890148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5069
Description: oral BD administration of 45 mg AZD5069
Study NCT02020863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed Loop
Description: Fluid management in the closed loop group will be performed via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to make frequent, regular and accurate adjustments to the amount of fluid the patient receives using feedback from standard operating room monitors.
Study NCT04025723 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Downhill running
Description: 60 minutes downhill running in 10% grade, in an effort of 65% of VO2max.
Study NCT01491048 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: THA Physiotherapy
Description: Patients will be randomized into two groups. The control group will receive care from the team of the THA Assistance Protocol already used by the HSG of HCPA without the intervention of physiotherapy. During hospitalization, the group of cases will be submitted to physical therapy associated with the intervention of the team of the THA Assistance Protocol.
Study NCT01491048 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No physiotherapy after THA
Description: No physiotherapy after THA
Study NCT01024413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gefitinib
Description: study arm.gefitinib 250 mg oral till disease progression
Study NCT01553890 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: blood sample, venous blood, about 10 ml will be drawn from participants
Study NCT01925456 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Toviaz
Description: Means of effectiveness, adherence, and utility instruments over time will be examined to evaluate whether changes are linear from baseline to 8 weeks and 3 months. We will demonstrate the validity and responsiveness of pragmatic instruments against existing established measures (Table 3).
Study NCT03644251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: amniotic and umbilical cord matrix
Description: Cryopreserved human amniotic and umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability.
Study NCT02887807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation
Description: cardio-pulmonary resuscitation usual care of cardiac arrest
Study NCT02887807 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single intravenous bolus of placebo at the onset of resuscitation
Description: cardio-pulmonary resuscitation usual care of cardiac arrest
Study NCT03872453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant
Description: A single dose of zavegepant
Study NCT03872453 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zavegepant matching placebo
Description: A single dose of placebo matched to zavegepant
Study NCT03872453 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Aptar Pharma Unit Dose System
Description: A single-dose intranasal device
Study NCT03872453 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intranasal Aptar Pharma Unit Dose System
Description: A single-dose intranasal device
Study NCT02956512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexibuprofen
Description: Dexibuprofen 300mg
Study NCT01678209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI scans
Description: 2 fMRI scans 6-8 weeks apart
Study NCT01678209 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fMRI scans
Description: 2 fMRI scans 6-8 weeks apart
Study NCT01678209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine arm
Description: Flexible dose titration with atomoxetine prescribed at weekly visits for 6-8 weeks
Study NCT01678209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate arm
Description: Flexible dose titration with methylphenidate for 6-8 weeks, with optional post study stabilization visits.
Study NCT04393051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib Oral Tablet
Description: Baricitinib will be administered by oral route at different dosages according to age and kidney function. The drug will be administered for 14 days, unless occurrence of discontinuation criteria.
Study NCT04694898 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard programme
Description: The control arm will receive national standard programme for women and children under the age of 2 years. This includes 1) national nutrition and health care including iron \& folic acid (IFA) supplementation in pregnancy; 2) early initiation and exclusive breastfeeding until 6 months of age; 3) timely introduction of liquid and semi-solid complementary foods; and 4) diversified complementary foods.